• Contact Us
  • Sign Up
  • TWITTER
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Microbiome Job Board

Finance

Finance

Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis

April 28, 2022 Microbiome Times

Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus […]

Finance

Microba Life Sciences Completes Successful IPO & Announces Partnership with Ginkgo Bioworks

April 4, 2022 Microbiome Times

Microba Life Sciences (ASX:MAP), a precision microbiome science company, commenced trading on the Australian Securities Exchange (ASX) on April 4th following the completion of an initial public offering (IPO). The IPO raised $30.0 million and […]

Finance

Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

April 4, 2022 Microbiome Times

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a […]

Finance

How insights from the field of advanced therapy medicinal products (ATMPs) can inform solutions in the microbiome field

March 23, 2022 Microbiome Times

Upcoming panel at Pharmabiotics Conference & Partnering 2022 will explore what microbiome drug developers can learn from another area of pharmaceutical innovation Live Biotherapeutic Products (LBPs) emerging from microbiome-related scientific innovation are novel and exciting […]

Finance

Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia

March 14, 2022 Microbiome Times

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, and BIOASTER, the first Institute for Technological Innovation in Microbiology, announce the implementation of research collaboration to use […]

Finance

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark

March 9, 2022 Microbiome Times

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern […]

Finance

Microbiotica raises $67M to advance pipeline of microbiome-based therapeutics

March 9, 2022 Microbiome Times

Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. […]

Finance

Recipharm acquires Arranta Bio

February 18, 2022 Microbiome Times

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the acquisition of Arranta Bio, a prominent advanced therapy CDMO. Under the stewardship of Mark Bamforth and backed by Ampersand Capital Partners, the […]

Finance

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

February 10, 2022 Microbiome Times

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a securities purchase agreement to […]

Finance

MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies

February 9, 2022 Microbiome Times

MaaT Pharma, a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer and Skyepharma, a Contract Development and Manufacturing Organization […]

Editor's Choice

ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

February 7, 2022 Craig Thomson and Jennifer Bailey

Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University.  […]

Posts navigation

1 2 … 21 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
    April 15, 2022
  • Did you miss Probiota Copenhagen 2022? Catch up now!
    April 12, 2022
  • A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology
    February 18, 2022
  • Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
    February 17, 2022
  • ELIGO v SNIPR: a reflection on IP strategies in a competitive environment
    February 7, 2022
sign up

Sign up to the Microbiome Times newsletter